Relypsa (Relypsa) FCF Margin % : -1,539.51% (As of Jun. 2016)

View and export this data going back to 2013. Start your Free Trial

What is Relypsa FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Relypsa's Free Cash Flow for the three months ended in Jun. 2016 was $-80.38 Mil. Relypsa's Revenue for the three months ended in Jun. 2016 was $5.22 Mil. Therefore, Relypsa's FCF Margin % for the quarter that ended in Jun. 2016 was -1,539.51%.

As of today, Relypsa's current FCF Yield % is -16.63%.

The historical rank and industry rank for Relypsa's FCF Margin % or its related term are showing as below:

RLYP' s FCF Margin % Range Over the Past 10 Years
Min: -632 Med: 0 Max: 0
Current: -632

RLYP's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -144.01 vs RLYP: -632.00

Relypsa FCF Margin % Historical Data

The historical data trend for Relypsa's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa FCF Margin % Chart

Relypsa Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

FCF Margin %

-641.24

Relypsa Quarterly Data
	Dec11	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
FCF Margin %	Get a 7-Day Free Trial												-	-181.18	-459.87	-655.55	-1,539.51

Competitive Comparison of Relypsa's FCF Margin %

For the Biotechnology subindustry, Relypsa's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relypsa's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Relypsa's FCF Margin % falls into.

Relypsa FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Relypsa's FCF Margin for the fiscal year that ended in Dec. 2015 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2015 )	/	Revenue (A: Dec. 2015 )
	=	-118.95	/	18.55
	=	-641.24 %

Relypsa's FCF Margin for the quarter that ended in Jun. 2016 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2016 )	/	Revenue (Q: Jun. 2016 )
	=	-80.378	/	5.221
	=	-1,539.51 %

Relypsa FCF Margin % Related Terms

Thank you for viewing the detailed overview of Relypsa's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Relypsa (Relypsa) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.relypsa.com

Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Executives

Ronald A. Krasnow	officer: See Remarks	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball	officer: Chief Financial Officer & SVP	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J	director	33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl	officer: SVP, Chief Technology Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland	officer: SVP & Chief Commercial Officer	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley	director	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi • 10-26-2015